- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Twentyeight-seven Therapeutics
Headquarters: Watertown, MA, United States
Website: http://www.twentyeight-seven...
Year Founded: 2016
Status: Private
BioCentury | Nov 30, 2022
Data Byte
Rgenta’s A round adds fuel to RNA-targeting small molecule space
$52M round led by AstraZeneca’s joint fund with China International Capital
BioCentury | Jul 21, 2021
Management Tracks
Passage Bio builds out C-suite
Plus: Rome, Adagio, Iveric, Renovacor and more
BioCentury | Apr 17, 2020
Emerging Company Profile
Rgenta: enhancing interactions between RNA and RNA-binding proteins
Rgenta’s small molecules act like glue between RNA and RNA-binding proteins
BioCentury | Jul 11, 2019
Emerging Company Profile
Twentyeight-Seven’s bet on RNA-binding proteins
Twentyeight-Seven is capitalizing on the emerging biology of RNA-binding proteins by targeting their interactions with non-coding RNAs
BioCentury | May 10, 2019
Financial News
May 10 Financial Quick Takes: Intercept raises over $400M; plus 28-7, LunaPBC
Items per page:
1 - 8 of 8